CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 143 enrolled
Drug / intervention
Lansoprazole +2 moredrug
Likely dose
Lansoprazole 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02755753
NCT02755753Phase 4Completed
CompareCT.gov

A Multicenter, Randomized, Double-blinded, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Rebamipide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (REPAIR)

YongChan Lee·interventional·Posted Apr 29, 2016·Updated Apr 29, 2016

In Brief

A Phase 4 clinical trial evaluating Lansoprazole, Rebamipide, and 1 other intervention for Gastroesophageal Reflux. Completed, enrolled 143 participants across 5 sites in 2 countries.

Detailed Summary

The purpose of this study is to evaluate whether Rebamipide facilitate the healing of inflamed mucosa as an adjuvant regimen in erosive reflux esophagitis (ERE).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroesophageal Reflux
CountriesChina, South Korea
CollaboratorsOtsuka Pharmaceutical Co., Ltd.

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 29, 2016
Enrollment StartJan 1, 2014
Primary CompletionJan 1, 2016
Study CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 10.2 years ago

Interventions

Lansoprazoledrug

Oral administration of Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast

Rebamipidedrug

Oral administration of Mucosta (rebamipide) 100 mg, 1 tablet, PO, tid, 30 minutes before breakfast, lunch, and dinner

Rebamipide-placebodrug

Oral administration of Mucosta®-placebo, 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner